FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC)
CUSIP: 31447P100
Q4 2019 13F Holders as of 31 Dec 2019
- Type / Class
- Equity / Common Shares, no par value
- Shares outstanding
- 34,763,175
- Total 13F shares
- 9,292,337
- Share change
- -6,307
- Total reported value
- $60,284,409
- Price per share
- $6.48
- Number of holders
- 26
- Value change
- -$38,066
- Number of buys
- 12
- Number of sells
- 9
Quarterly Holders Quick Answers
What is CUSIP 31447P100?
CUSIP 31447P100 identifies FENC - FENNEC PHARMACEUTICALS INC. - Common Shares, no par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 31447P100:
Top shareholders of FENC - FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Southpoint Capital Advisors LP |
13F
|
Company |
11%
|
3,997,214
|
$19,227,000 | — | 30 Sep 2019 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
3.2%
|
1,105,999
|
$5,320,000 | — | 30 Sep 2019 | |
| 683 Capital Management, LLC |
13F
|
Company |
2.8%
|
971,351
|
$4,672,000 | — | 30 Sep 2019 | |
| Solas Capital Management, LLC |
13F
|
Company |
2.7%
|
943,200
|
$4,537,000 | — | 30 Sep 2019 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
720,000
|
$3,463,000 | — | 30 Sep 2019 | |
| Granahan Investment Management, LLC |
13F
|
Company |
1.3%
|
455,979
|
$2,193,000 | — | 30 Sep 2019 | |
| OXFORD ASSET MANAGEMENT LLP |
13F
|
Company |
0.24%
|
82,749
|
$398,000 | — | 30 Sep 2019 | |
| Paloma Partners Management Co |
13F
|
Company |
0.12%
|
42,832
|
$206,000 | — | 30 Sep 2019 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.1%
|
34,972
|
$168,000 | — | 30 Sep 2019 | |
| Hartford Financial Management Inc. |
13F
|
Company |
0.09%
|
30,000
|
$144,000 | — | 30 Sep 2019 | |
| Weiss Multi-Strategy Advisers LLC |
13F
|
Company |
0.07%
|
25,000
|
$120,000 | — | 30 Sep 2019 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.06%
|
22,040
|
$106,000 | — | 30 Sep 2019 | |
| WEDBUSH SECURITIES INC |
13F
|
Company |
0.03%
|
11,900
|
$57,000 | — | 30 Sep 2019 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.03%
|
9,347
|
$45,000 | — | 30 Sep 2019 | |
| MEEDER ASSET MANAGEMENT INC |
13F
|
Company |
0.02%
|
6,754
|
$32,000 | — | 30 Sep 2019 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
2,302
|
$11,000 | — | 30 Sep 2019 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
1,416
|
$6,811 | — | 30 Sep 2019 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
1,308
|
$6,000 | — | 30 Sep 2019 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
805
|
$4,000 | — | 30 Sep 2019 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
410
|
$2,000 | — | 30 Sep 2019 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0%
|
270
|
$1,000 | — | 30 Sep 2019 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
110
|
$1,000 | — | 30 Sep 2019 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
1
|
$5 | — | 30 Sep 2019 |
Institutional Holders of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) as of Q4 2019
As of 31 Dec 2019,
FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,292,337 shares.
The largest 10 holders included
Southpoint Capital Advisors LP, Avoro Capital Advisors LLC, Solas Capital Management, LLC, 683 Capital Management, LLC, Sonic Fund II, L.P., EVENTIDE ASSET MANAGEMENT, LLC, GRANAHAN INVESTMENT MANAGEMENT INC/MA, OXFORD ASSET MANAGEMENT LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and Hartford Financial Management Inc..
This page lists
26
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2019 vs Q3 2019 Across Filers
Q3 2019 holders
21
Q4 2019 holders
26
Holder diff
5
| Investor | Q3 2019 Shares | Q4 2019 Shares | Share Diff | Share Chg % | Q3 2019 Value $ | Q4 2019 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.